CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...

Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...

Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkersCM24 ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support ...

Four years of research exploring the post-pandemic mental health landscape culminates in this year's SeekHer Shift Report, "Activating Agency & Advocacy in Women's Mental Health." Supported by leading ...

The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action date of April 3. Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.